

# **Alzheimer Disease**

## **Part II: Markets & Companies**

**by**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**November 2021**

**A Jain PharmaBiotech Report**

## AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced, and held academic positions in several countries including Switzerland, India, Iran, Germany, Canada, and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 490 publications include 35 books (6 as editor+ 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals, biomarkers: proteomics, molecular diagnostics, nanobiotechnology, and personalized medicine. Contributions to MedLink, an accredited continuing education program for neurologists, include 172 articles out of a total of 1200 articles by 450 authors. These articles are updated on a yearly basis.

Prof. Jain's earlier books were the first in the areas covered: "Handbook of Laser Neurosurgery" (Charles C. Thomas, Springfield, Ill, 1983) and "Textbook of Hyperbaric Medicine" (1st ed in 1990 and 6th ed by Springer, 2017). His "Textbook of Gene Therapy" was translated into Chinese in 2000. Recent books include "Handbook of Nanomedicine" (Springer 2008, Chinese edition by Peking University Press 2011, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese ed, Chemical Industry Press 2016, 2nd ed 2017), "Drug-induced Neurological Disorders", 4th ed (Springer 2021), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has also edited 3 editions of "Drug Delivery System" (Springer 2008, 20012 and 2018) and "Applied Neurogenomics" (Springer 2015). Lectures on personalized medicine given at Kazakh National Medical University, Kazakhstan were translated into Russian and published as a book "Essentials of Personalized Medicine" (LITERRA Publishing House, Moscow, 2019). He is currently writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

**November 2021 (first edition in 2003)**  
**Copyright © 2021 by**

**Jain PharmaBiotech**  
**Bläsiring 7**  
**CH-4057 Basel**  
**Switzerland**

**Tel & Fax:** +4161-6924461  
**Email:** [info@pharmabiotech.ch](mailto:info@pharmabiotech.ch)  
**Web site:** <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>8. Markets &amp; Finances of AD Care .....</b>	<b>6</b>
<b>Introduction .....</b>	<b>6</b>
<b>Pharmacoeconomics of treatment of AD .....</b>	<b>6</b>
Quality of Life in relation to economics of AD .....	6
Costs associated with Alzheimer disease .....	6
Pharmacoeconomics of donepezil .....	7
Pharmacoeconomics studies using rivastigmine .....	7
Pharmacoeconomics studies using galantamine .....	8
Pharmacoeconomics studies using memantine.....	8
<b>Epidemiology of AD.....</b>	<b>8</b>
<b>Patterns of AD care in major markets .....</b>	<b>9</b>
Care of AD patients in the US .....	9
<i>Cost of care.....</i>	<i>9</i>
<i>Medicare and AD.....</i>	<i>10</i>
<i>Patterns of practice in AD care.....</i>	<i>11</i>
<i>Opinions of physicians' organizations on drugs for dementia.....</i>	<i>11</i>
Care of AD patients in the UK .....	12
<i>Cost of care.....</i>	<i>12</i>
<i>Patterns of practice in AD care.....</i>	<i>12</i>
<i>NICE recommendations to NHS.....</i>	<i>13</i>
Care of AD patients in Germany .....	14
Care of AD patients in France .....	15
Care of AD patients in Italy .....	15
Care of AD patients in Spain.....	16
Care of AD patients in Japan .....	16
<b>Markets for AD diagnostics .....</b>	<b>16</b>
<b>Markets for AD therapeutics .....</b>	<b>17</b>
Geographical markets for AD .....	17
Markets for currently approved drugs for AD .....	17
Markets for generic AD drugs .....	18
Statins.....	18
Future growth of AD market.....	19
<b>Limitations of AD drug development by the biotechnology industry .....</b>	<b>19</b>
<b>Unmet needs in the management of AD .....</b>	<b>20</b>
<b>Drivers of AD markets.....</b>	<b>21</b>
Increase of the aged populations .....	22
Increase in the number of approved drugs for AD .....	22
Limitations of the current therapies.....	22
Improvements in diagnosis .....	22
Increasing awareness of the disease .....	23
Support for AD research .....	23
<b>9. Companies .....</b>	<b>24</b>
<b>Introduction .....</b>	<b>24</b>
<b>Profiles of companies.....</b>	<b>24</b>
<b>Collaborations.....</b>	<b>144</b>
<b>10. References.....</b>	<b>148</b>

## Tables

Table 8-1: Prevalence of AD in major markets 2020-2030 .....	9
Table 8-2: Direct and indirect costs associated with Alzheimer disease .....	9
Table 8-3: AD market values from 2020-2030 in major world markets .....	17
Table 8-4: Markets for currently approved AD drugs 2020-2030 .....	18
Table 8-5: Potential markets for drugs in development 2020-2030 .....	19
Table 8-6: Limitations of AD drug development by the biotechnology industry.....	19
Table 8-7: Factors that drive AD markets .....	21
Table 9-1: Major players in Alzheimer's disease therapeutics.....	24
Table 9-2: Collaborations relevant to Alzheimer disease .....	144

## Figures

Figure 8-1: Unmet needs in the management of Alzheimer disease .....	21
--	----